The role of anti-Müllerian hormone in polycystic ovary syndrome_West China Medical Journal

Authors：

ZHANG Yizhuo ¹ ,  ZHANG Yuehui ¹ , HAN Yanhua ¹ , WANG Lijing ² , LIU Chang ² , ZHANG Jiao ³

1. the First Department of Gynaecology, the First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150040, P. R. China;
2. Department of Obstetrics and Gynecology, the First Hospital of Harbin, Harbin, Heilongjiang 150010, P. R. China;
3. Traditional Chinese Medicine Hall, the Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang 150001, P. R. China;

Corresponding?author：

ZHANG Yuehui, Email: chizishui-04@163.com

Keywords：

Anti-Müllerian hormone; Polycystic ovary syndrome; Follicular development

DOI：

10.7507/1002-0179.201911250

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Polycystic ovary syndrome is one of the common reproductive endocrine diseases in women in recent years. A large number of studies have found that serum anti-Müllerian hormone levels in patients with polycystic ovary syndrome are significantly higher than those in normal women, especially in anovulatory patients with polycystic ovary syndrome. This article briefly introduces the relationship between follicular development, hyperandrogenemia, obesity, and insulin resistance in the pathological manifestations of polycystic ovary syndrome and anti-Müllerian hormone, and the application of anti-Müllerian hormone in assisted reproduction, ovarian reserve and diagnosis in patients with polycystic ovary syndrome. It aims to provide a basis for better use of anti-Müllerian in the diagnosis and treatment of polycystic ovary syndrome.

Citation： ZHANG Yizhuo, ZHANG Yuehui, HAN Yanhua, WANG Lijing, LIU Chang, ZHANG Jiao. The role of anti-Müllerian hormone in polycystic ovary syndrome. West China Medical Journal, 2020, 35(11): 1399-1403. doi: 10.7507/1002-0179.201911250 Copy

1.	Homburg R, Crawford G. The role of AMH in anovulation associated with PCOS: a hypothesis. Hum Reprod, 2014, 29(6): 1117-1121.
2.	Saxena U, Ramani M, Singh P. Role of AMH as diagnostic tool for polycystic ovarian syndrome. J Obstet Gynaecol India, 2018, 68(2): 117-122.
3.	Dumont A, Robin G, Catteau-Jonard S, et al. Role of anti-Müllerian hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome: a review. Reprod Biol Endocrinol, 2015, 13: 137.
4.	Shi Y, Li L, Zhou J, et al. Efficacy of electroacupuncture in regulating the imbalance of AMH and FSH to improve follicle development and hyperandrogenism in PCOS rats. Biomed Pharmacother, 2019, 113: 108687.
5.	Matsuzaki T, Munkhzaya M, Iwasa T, et al. Relationship between serum anti-Mullerian hormone and clinical parameters in polycystic ovary syndrome. Endocr J, 2017, 64(5): 531-541.
6.	張欣, 鄧琳琳. 雄激素抑制劑對 PCOS 患者血清 AMH 等指標的影響初探. 現代婦產科進展, 2012, 21(6): 482-483.
7.	梁光林, 鄭文玲, 劉傳勇, 等. PCOS 患者內分泌代謝異常與 AMH 水平的關系研究. 中國醫藥科學, 2018, 8(15): 254-256.
8.	彭璇, 李霞, 辜敏. 多囊卵巢綜合征患者血清抗苗勒氏管激素與游離睪酮指數的相關性研究. 中國婦幼保健, 2015, 30(34): 5960-5962.
9.	Gorsic LK, Kosova G, Werstein B, et al. Pathogenic anti-Müllerian hormone variants in polycystic ovary syndrome. J Clin Endocrinol Metab, 2017, 102(8): 2862-2872.
10.	李金萍, 王焱. 高雄激素和非高雄激素型多囊卵巢綜合征患者血清抗苗勒管激素分泌特點及診斷效能比較. 實用婦科內分泌電子雜志, 2017, 4(5): 50, 52.
11.	王小霞, 鄧翠. PCOS 患者血清 AMH 水平與胰島素抵抗及雄激素的相關性研究. 湖北民族學院學報(醫學版), 2017, 34(2): 8-10, 14.
12.	Bothou A, Koutlaki N, Iatrakis G, et al. AntiMüllerian hormone as indicator of ovarian dysfunction. Acta Endocrinol (Buchar), 2017, 13(2): 237-245.
13.	Verma AK, Rajbhar S, Mishra J, et al. Anti-Mullerian hormone:a marker of ovarian reserve and its association with polycystic ovarian syndrome. J Clin Diagn Res, 2016, 10(12): QC10-QC12.
14.	周密, 丁旭, 宋暉, 等. 多囊卵巢綜合征患者血清抗苗勒管激素與肥胖、胰島素抵抗程度的相關性分析. 現代生物醫學進展, 2018, 18(10): 1916-1921.
15.	劉增娟, 徐磊. 多囊卵巢綜合征患者血清抗苗勒氏管激素水平與胰島素抵抗及雄激素的相關性評價. 中外醫療, 2019, 38(23): 26-28.
16.	余莎, 劉明銘, 關嵩青, 等. 多囊卵巢綜合征患者血清 AMH 與胰島素抵抗水平的關系. 深圳中西醫結合雜志, 2017, 27(1): 1-3.
17.	Foroozanfard F, Samimi M, Almadani KH, et al. Effect of metformin on the anti-Müllerian hormone level in infertile women with polycystic ovarian syndrome. Electron Physician, 2017, 9(12): 5969-5973.
18.	Szafarowska M, Dziech E, Kaleta B, et al. Anti-Müllerian hormone level is associated with vitamin D receptor polymorphisms in women with polycystic ovary syndrome. J Assist Reprod Genet, 2019, 36(6): 1281-1289.
19.	Zhang JF, Yu CM, Yan LL, et al. Effect of anti-mullerian hormone on stem cell factor in serum, follicular fluid and ovarian granular cells of polycystic ovarian syndrome patients. Eur Rev Med Pharmacol Sci, 2018, 22(22): 7877-7882.
20.	Arslan E, Gorkem U, Togrul C. Is there a relationship between vitamin D deficiency status and PCOS in infertile women?. Geburtshilfe Frauenheilkd, 2019, 79(7): 723-730.
21.	Vembu R, Reddy NS. Serum AMH level to predict the hyper response in women with PCOS and non-PCOS undergoing controlled ovarian stimulation in ART. J Hum Reprod Sci, 2017, 10(2): 91-94.
22.	于艷麗, 劉秀榮, 姚淑紅. 血清抗苗勒管激素、黃體生成激素水平與多囊卵巢綜合征不孕患者促排卵療效的關系. 蘭州大學學報(醫學版), 2019, 45(4): 10-13, 19.
23.	歐陽璐, 王恩銀, 李婧, 等. 抗苗勒管激素水平對多囊卵巢綜合征患者行卵泡期長效長方案助孕結局的影響. 生殖醫學雜志, 2019, 28(5): 451-456.
24.	Christiansen SC, Eilertsen TB, Vanky E, et al. Does AMH reflect follicle number similarly in women with and without PCOS?. PLoS One, 2016, 11(1): e0146739.
25.	張琦, 湯美玲, 沈澍. 血清 AMH 聯合性激素檢測在診斷多囊卵巢綜合征患者中的應用研究. 中國實驗診斷學, 2019, 23(8): 1344-1346.
26.	范蕓, 解娟, 施瑞潔, 等. 抗苗勒氏管激素和卵泡刺激素對多囊卵巢綜合征的診斷效能研究. 中國臨床藥理學雜志, 2019, 35(21): 2665-2667.
27.	Kim JY, Tfayli H, Michaliszyn SF, et al. Anti-Müllerian hormone in obese adolescent girls with polycystic ovary syndrome. J Adolesc Health, 2017, 60(3): 333-339.
28.	Song DK, Oh JY, Lee H, et al. Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Müllerian hormone cutoff value. Korean J Intern Med, 2017, 32(4): 690-698.
29.	Yue CY, Lu LK, Li M, et al. Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women. PLoS One, 2018, 13(8): e0203129.
30.	Aydo?mu? H, Kelek?i S, Elmal? F, et al. Can we use serum anti-Mullerian hormone to differentiate the diagnosis between polycystic ovary syndrome patients and healthy women with polycystic ovarian morphology and regular menstrual cycles. Saudi Med J, 2018, 39(10): 1011-1016.
31.	陳穎, 陸婁凱奕, 張倩嵐, 等. 抗苗勒管激素和內分泌代謝指標在多囊卵巢綜合征診斷中的應用. 中華生殖與避孕雜志, 2018, 38(10): 847-851.
32.	Tokmak A, Timur H, Aksoy RT, et al. Is anti-Mullerian hormonea good diagnostic marker for adolescent and young adult patients with Polycystic ovary syndrome?. Turk J Obstet Gynecol, 2015, 12(4): 199-204.

1. Homburg R, Crawford G. The role of AMH in anovulation associated with PCOS: a hypothesis. Hum Reprod, 2014, 29(6): 1117-1121.
2. Saxena U, Ramani M, Singh P. Role of AMH as diagnostic tool for polycystic ovarian syndrome. J Obstet Gynaecol India, 2018, 68(2): 117-122.
3. Dumont A, Robin G, Catteau-Jonard S, et al. Role of anti-Müllerian hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome: a review. Reprod Biol Endocrinol, 2015, 13: 137.
4. Shi Y, Li L, Zhou J, et al. Efficacy of electroacupuncture in regulating the imbalance of AMH and FSH to improve follicle development and hyperandrogenism in PCOS rats. Biomed Pharmacother, 2019, 113: 108687.
5. Matsuzaki T, Munkhzaya M, Iwasa T, et al. Relationship between serum anti-Mullerian hormone and clinical parameters in polycystic ovary syndrome. Endocr J, 2017, 64(5): 531-541.
6. 張欣, 鄧琳琳. 雄激素抑制劑對 PCOS 患者血清 AMH 等指標的影響初探. 現代婦產科進展, 2012, 21(6): 482-483.
7. 梁光林, 鄭文玲, 劉傳勇, 等. PCOS 患者內分泌代謝異常與 AMH 水平的關系研究. 中國醫藥科學, 2018, 8(15): 254-256.
8. 彭璇, 李霞, 辜敏. 多囊卵巢綜合征患者血清抗苗勒氏管激素與游離睪酮指數的相關性研究. 中國婦幼保健, 2015, 30(34): 5960-5962.
9. Gorsic LK, Kosova G, Werstein B, et al. Pathogenic anti-Müllerian hormone variants in polycystic ovary syndrome. J Clin Endocrinol Metab, 2017, 102(8): 2862-2872.
10. 李金萍, 王焱. 高雄激素和非高雄激素型多囊卵巢綜合征患者血清抗苗勒管激素分泌特點及診斷效能比較. 實用婦科內分泌電子雜志, 2017, 4(5): 50, 52.
11. 王小霞, 鄧翠. PCOS 患者血清 AMH 水平與胰島素抵抗及雄激素的相關性研究. 湖北民族學院學報(醫學版), 2017, 34(2): 8-10, 14.
12. Bothou A, Koutlaki N, Iatrakis G, et al. AntiMüllerian hormone as indicator of ovarian dysfunction. Acta Endocrinol (Buchar), 2017, 13(2): 237-245.
13. Verma AK, Rajbhar S, Mishra J, et al. Anti-Mullerian hormone:a marker of ovarian reserve and its association with polycystic ovarian syndrome. J Clin Diagn Res, 2016, 10(12): QC10-QC12.
14. 周密, 丁旭, 宋暉, 等. 多囊卵巢綜合征患者血清抗苗勒管激素與肥胖、胰島素抵抗程度的相關性分析. 現代生物醫學進展, 2018, 18(10): 1916-1921.
15. 劉增娟, 徐磊. 多囊卵巢綜合征患者血清抗苗勒氏管激素水平與胰島素抵抗及雄激素的相關性評價. 中外醫療, 2019, 38(23): 26-28.
16. 余莎, 劉明銘, 關嵩青, 等. 多囊卵巢綜合征患者血清 AMH 與胰島素抵抗水平的關系. 深圳中西醫結合雜志, 2017, 27(1): 1-3.
17. Foroozanfard F, Samimi M, Almadani KH, et al. Effect of metformin on the anti-Müllerian hormone level in infertile women with polycystic ovarian syndrome. Electron Physician, 2017, 9(12): 5969-5973.
18. Szafarowska M, Dziech E, Kaleta B, et al. Anti-Müllerian hormone level is associated with vitamin D receptor polymorphisms in women with polycystic ovary syndrome. J Assist Reprod Genet, 2019, 36(6): 1281-1289.
19. Zhang JF, Yu CM, Yan LL, et al. Effect of anti-mullerian hormone on stem cell factor in serum, follicular fluid and ovarian granular cells of polycystic ovarian syndrome patients. Eur Rev Med Pharmacol Sci, 2018, 22(22): 7877-7882.
20. Arslan E, Gorkem U, Togrul C. Is there a relationship between vitamin D deficiency status and PCOS in infertile women?. Geburtshilfe Frauenheilkd, 2019, 79(7): 723-730.
21. Vembu R, Reddy NS. Serum AMH level to predict the hyper response in women with PCOS and non-PCOS undergoing controlled ovarian stimulation in ART. J Hum Reprod Sci, 2017, 10(2): 91-94.
22. 于艷麗, 劉秀榮, 姚淑紅. 血清抗苗勒管激素、黃體生成激素水平與多囊卵巢綜合征不孕患者促排卵療效的關系. 蘭州大學學報(醫學版), 2019, 45(4): 10-13, 19.
23. 歐陽璐, 王恩銀, 李婧, 等. 抗苗勒管激素水平對多囊卵巢綜合征患者行卵泡期長效長方案助孕結局的影響. 生殖醫學雜志, 2019, 28(5): 451-456.
24. Christiansen SC, Eilertsen TB, Vanky E, et al. Does AMH reflect follicle number similarly in women with and without PCOS?. PLoS One, 2016, 11(1): e0146739.
25. 張琦, 湯美玲, 沈澍. 血清 AMH 聯合性激素檢測在診斷多囊卵巢綜合征患者中的應用研究. 中國實驗診斷學, 2019, 23(8): 1344-1346.
26. 范蕓, 解娟, 施瑞潔, 等. 抗苗勒氏管激素和卵泡刺激素對多囊卵巢綜合征的診斷效能研究. 中國臨床藥理學雜志, 2019, 35(21): 2665-2667.
27. Kim JY, Tfayli H, Michaliszyn SF, et al. Anti-Müllerian hormone in obese adolescent girls with polycystic ovary syndrome. J Adolesc Health, 2017, 60(3): 333-339.
28. Song DK, Oh JY, Lee H, et al. Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Müllerian hormone cutoff value. Korean J Intern Med, 2017, 32(4): 690-698.
29. Yue CY, Lu LK, Li M, et al. Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women. PLoS One, 2018, 13(8): e0203129.
30. Aydo?mu? H, Kelek?i S, Elmal? F, et al. Can we use serum anti-Mullerian hormone to differentiate the diagnosis between polycystic ovary syndrome patients and healthy women with polycystic ovarian morphology and regular menstrual cycles. Saudi Med J, 2018, 39(10): 1011-1016.
31. 陳穎, 陸婁凱奕, 張倩嵐, 等. 抗苗勒管激素和內分泌代謝指標在多囊卵巢綜合征診斷中的應用. 中華生殖與避孕雜志, 2018, 38(10): 847-851.
32. Tokmak A, Timur H, Aksoy RT, et al. Is anti-Mullerian hormonea good diagnostic marker for adolescent and young adult patients with Polycystic ovary syndrome?. Turk J Obstet Gynecol, 2015, 12(4): 199-204.

Previous Article
Progress of sedation and analgesia in the pediatric emergency department
Next Article
CT texture analysis in gastric cancers

West China Medical Journal

The role of anti-Müllerian hormone in polycystic ovary syndrome

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content